Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transthyretin-Mediated Amyloidosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02319005
What this trial is testing

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Who this might be right for
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)Amyloidosis, HereditaryAmyloid Neuropathies, Familial+3 more
Alnylam Pharmaceuticals 206
Large-scale testing (Phase 3)Active Not RecruitingNCT05071300
What this trial is testing

Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Who this might be right for
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Ionis Pharmaceuticals, Inc. 151
Not applicableApproved For MarketingNCT02939820
What this trial is testing

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Who this might be right for
TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, Familial+3 more
Alnylam Pharmaceuticals
Early research (Phase 1)Study completedNCT02797847
What this trial is testing

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Who this might be right for
Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
Alnylam Pharmaceuticals 80
Not applicableNo Longer AvailableNCT05505838
What this trial is testing

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin-mediated Amyloidosis With CardiomyopathyATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Not applicableLooking for participantsNCT06465810
What this trial is testing

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Who this might be right for
Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more
AstraZeneca 1,850
Very early researchWithdrawnNCT04569903
What this trial is testing

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Who this might be right for
Transthyretin Amyloidosis
Yale University
Not applicableActive Not RecruitingNCT06360289
What this trial is testing

Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

Who this might be right for
Hereditary Amyloidosis, Transthyretin-RelatedAsymptomatic Carrier State
Alnylam Pharmaceuticals 346
Post-approval studies (Phase 4)Ended earlyNCT04306510
What this trial is testing

Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN

Who this might be right for
Hereditary Transthyretin Amyloidosis With Polyneuropthy
Akcea Therapeutics 8
Testing effectiveness (Phase 2)Study completedNCT01961921
What this trial is testing

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 27
Large-scale testing (Phase 3)Study completedNCT01960348
What this trial is testing

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Who this might be right for
TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, Familial+3 more
Alnylam Pharmaceuticals 225
Large-scale testing (Phase 3)Study completedNCT03862807
What this trial is testing

Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Who this might be right for
Amyloidosis, FamilialTransthyretin Amyloidosis
Alnylam Pharmaceuticals 24
Not applicableStudy completedNCT06073574
What this trial is testing

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. 160
Large-scale testing (Phase 3)Enrolling By InvitationNCT05667493
What this trial is testing

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. 1,400
Early research (Phase 1)Study completedNCT06527755
What this trial is testing

Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers

Who this might be right for
Transthyretin-mediated Amyloidosis
AstraZeneca 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT07608354
What this trial is testing

Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

Who this might be right for
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca 326
Early research (Phase 1)Study completedNCT02053454
What this trial is testing

The Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

Who this might be right for
Transthyretin (TTR)-Mediated Amyloidosis
Alnylam Pharmaceuticals 12
Early research (Phase 1)Study completedNCT01148953
What this trial is testing

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

Who this might be right for
Transthyretin Mediated Amyloidosis (ATTR)
Alnylam Pharmaceuticals 32
Large-scale testing (Phase 3)WithdrawnNCT04418024
What this trial is testing

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

Who this might be right for
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Eidos Therapeutics, a BridgeBio company
Not applicableLooking for participantsNCT04561518
What this trial is testing

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Who this might be right for
Transthyretin-Mediated AmyloidosisATTR Amyloidosis
Alnylam Pharmaceuticals 1,500
Next Page